Focus: ZOLL is a 5,000+ employee medical device company headquartered in San Jose, specializing in defibrillators and acute care resuscitation devices across cardiovascular, neurology, and respiratory markets.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Hot — 159 jobs added in 30d
Net +55 (159 new, 104 removed). Aggressive expansion phase.
Recent layoff filing — 96 affected
Source: state DOL filings via Big Local News
ZOLL is a stable, mission-driven medical device employer ideal for engineers and commercial professionals seeking job security and meaningful impact, but offers limited early-stage research opportunity.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Flagship wearable device appearing across multiple indications in pipeline; represents differentiated, non-implantable approach to arrhythmia management.
Help build intelligence for Zoll
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Zoll's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Core resuscitation device with established market presence; central to ZOLL's emergency care portfolio.
Automated external defibrillator with simplified electrode system; widely deployed in public access settings.
Imaging-Based FFR on Par With Wire for PCI Outcomes - MedPage Today
Imaging-Based FFR on Par With Wire for PCI Outcomes MedPage Today
Multimechanism Heart Failure Treatment for Post- hospitalized HFpEF and HFmrEF Patients - Medscape
Multimechanism Heart Failure Treatment for Post- hospitalized HFpEF and HFmrEF Patients Medscape
Sudden Cardiac Death Risk and Heart Failure Management at ACC.26 – How ZOLL Innovations Redefine Protection - PharmiWeb.com
Sudden Cardiac Death Risk and Heart Failure Management at ACC.26 – How ZOLL Innovations Redefine Protection PharmiWeb.com
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
No visible compliance, regulatory, or employment actions detected; clean operational profile.
Recent peer-reviewed publications with author affiliations at this company
Changes in quality of life in patients with atrial fibrillation and central sleep apnea treated with transvenous phrenic nerve stimulation.
The impact of defibrillation current and pad position on return of spontaneous circulation during refractory ventricular fibrillation.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo